Payment overview · 2025
General Payments
$3,934.69
80 reported records · 20 companies
Healthcare provider profile · identity verified
Vincent A.K. Ho, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Geriatric Medicine · LANCASTER, CA · NPI 1124138359
Verified facts
What the public records show
CMS Open Payments records show Vincent A.K. Ho, M.D. received $3,934.69 in general payments during 2025 across 80 reported records.
AstraZeneca Pharmaceuticals LP accounted for 20.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Kerendia, Mounjaro, Otezla, Ozempic, Rexulti, Rybelsus, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Vraylar by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Otezla by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 147 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 227 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 204 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 147 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 128 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 261 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 227 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Paxlovid by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SOLIQUA 100/33 as an associated drug or biological on 43 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Soliqua 100-33 by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $815.85 | 20.7% | 14 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $545.80 | 13.9% | 8 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $363.80 | 9.2% | 6 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $341.13 | 8.7% | 6 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $266.09 | 6.8% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $259.16 | 6.6% | 9 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $180.78 | 4.6% | 3 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $169.73 | 4.3% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $158.96 | 4.0% | 6 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $157.60 | 4.0% | 6 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $138.26 | 3.5% | 2 | 2025 |
| Regeneron Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $129.94 | 3.3% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $116.23 | 3.0% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $114.79 | 2.9% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $47.25 | 1.2% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $41.72 | 1.1% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $24.99 | 0.6% | 1 | 2025 |
| Tandem Diabetes Care, Inc. | Unresolved — no canonical attribution shown | $24.23 | 0.6% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $21.30 | 0.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.08 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,784.69 | 79 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $150.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $576.89 | 8 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $288.05 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $273.29 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $272.51 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $220.09 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $218.62 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $188.89 | 4 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $180.78 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $157.60 | 6 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $151.29 | 5 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $134.16 | 8 | 2025 |
Source payment records
|
|||||
| EYLEA Normalized: eylea |
Biological | Regeneron Pharmaceuticals, Inc. | $129.94 | 1 | 2025 |
Source payment records
|
|||||
| EYLEA HD Normalized: eylea hd |
Biological | Regeneron Pharmaceuticals, Inc. | $129.94 | 1 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $121.04 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $116.23 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $114.79 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $93.64 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $72.36 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $66.33 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $33.96 | 5 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $24.99 | 1 | 2025 |
Source payment records
|
|||||
| t:slim X2 Insulin Pump with Control-IQ Normalized: t slim x2 insulin pump with control iq |
Device | Tandem Diabetes Care, Inc. | $24.23 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $23.26 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $22.64 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $21.30 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $19.73 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.08 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 227 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 99 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 147 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 58 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 128 | exact normalized | Medicare Part D |
| OTEZLA otezla |
2025 | Otezla | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 261 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 96 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 204 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
76 | 32 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
70 | 21 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
99 | 30 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
58 | 12 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
147 | 46 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
227 | 62 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
204 | 50 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
147 | 46 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
128 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
44 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
261 | 58 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
96 | 23 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
227 | 62 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
19 | 18 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | SOLIQUA 100/33 open payments reported associated product |
CMS Open Payments — General Payments 43 supporting records · 15 recipient NPIs · example record 1233224976 |
Soliqua 100-33 · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1303 | 401 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 1123 | 172 |
| Amlodipine Besylate | Amlodipine Besylate | 830 | 242 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 716 | 161 |
| Levothyroxine Sodium | Levothyroxine Sodium | 626 | 174 |
| Gabapentin | Gabapentin | 560 | 144 |
| Losartan Potassium | Losartan Potassium | 537 | 170 |
| Lisinopril | Lisinopril | 469 | 147 |
| Pantoprazole Sodium | Pantoprazole Sodium | 467 | 141 |
| Metformin Hcl | Metformin Hcl | 447 | 134 |
| Alprazolam | Alprazolam | 425 | 81 |
| Omeprazole | Omeprazole | 358 | 105 |
| Hydrochlorothiazide | Hydrochlorothiazide | 344 | 96 |
| Metoprolol Succinate | Metoprolol Succinate | 344 | 104 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 319 | 60 |
| Tamsulosin Hcl | Tamsulosin Hcl | 301 | 96 |
| Furosemide | Furosemide | 296 | 102 |
| Tramadol Hcl | Tramadol Hcl | 284 | 90 |
| Ozempic | Semaglutide | 261 | 58 |
| Ibuprofen | Ibuprofen | 242 | 61 |
| Eliquis | Apixaban | 227 | 62 |
| Simvastatin | Simvastatin | 221 | 69 |
| Pravastatin Sodium | Pravastatin Sodium | 220 | 67 |
| Famotidine | Famotidine | 216 | 73 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 204 | 50 |
| Alendronate Sodium | Alendronate Sodium | 199 | 58 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 196 | 58 |
| Trazodone Hcl | Trazodone Hcl | 193 | 53 |
| Metoprolol Tartrate | Metoprolol Tartrate | 187 | 59 |
| Zolpidem Tartrate | Zolpidem Tartrate | 181 | 31 |
| Fluticasone Propionate | Fluticasone Propionate | 178 | 64 |
| Lorazepam | Lorazepam | 175 | 44 |
| Carvedilol | Carvedilol | 160 | 51 |
| Baclofen | Baclofen | 156 | 48 |
| Escitalopram Oxalate | Escitalopram Oxalate | 152 | 37 |
| Jardiance | Empagliflozin | 147 | 46 |
| Montelukast Sodium | Montelukast Sodium | 140 | 40 |
| Allopurinol | Allopurinol | 133 | 36 |
| Clopidogrel | Clopidogrel Bisulfate | 132 | 50 |
| Atenolol | Atenolol | 129 | 34 |
| Tizanidine Hcl | Tizanidine Hcl | 129 | 40 |
| Carisoprodol | Carisoprodol | 128 | 17 |
| Mounjaro | Tirzepatide | 128 | 25 |
| Oxycodone Hcl | Oxycodone Hcl | 123 | 24 |
| Potassium Chloride | Potassium Chloride | 122 | 41 |
| Duloxetine Hcl | Duloxetine Hcl | 120 | 28 |
| Benazepril Hcl | Benazepril Hcl | 118 | 30 |
| Glipizide | Glipizide | 117 | 41 |
| Mirtazapine | Mirtazapine | 115 | 26 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 114 | 28 |
| Temazepam | Temazepam | 114 | 24 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 114 | 37 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 111 | 34 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 108 | 29 |
| Donepezil Hcl | Donepezil Hcl | 108 | 36 |
| Memantine Hcl | Memantine Hcl | 105 | 31 |
| Diclofenac Sodium | Diclofenac Sodium | 103 | 37 |
| Cephalexin | Cephalexin | 101 | 76 |
| Farxiga | Dapagliflozin Propanediol | 99 | 30 |
| Azithromycin | Azithromycin | 98 | 82 |
| Meclizine Hcl | Meclizine Hcl | 98 | 30 |
| Rybelsus | Semaglutide | 96 | 23 |
| Prednisone | Prednisone | 95 | 30 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 92 | 30 |
| Morphine Sulfate Er | Morphine Sulfate | 92 | 14 |
| Xarelto | Rivaroxaban | 92 | 26 |
| Amoxicillin | Amoxicillin | 91 | 64 |
| Nebivolol Hcl | Nebivolol Hcl | 89 | 24 |
| Valsartan | Valsartan | 89 | 26 |
| Glimepiride | Glimepiride | 87 | 28 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 86 | 29 |
| Lovastatin | Lovastatin | 84 | 23 |
| Finasteride | Finasteride | 83 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 81 | 24 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 79 | 24 |
| Pregabalin | Pregabalin | 78 | 21 |
| Linzess | Linaclotide | 76 | 32 |
| Diazepam | Diazepam | 74 | 14 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 73 | 36 |
| Sertraline Hcl | Sertraline Hcl | 73 | 28 |
| Synthroid | Levothyroxine Sodium | 70 | 21 |
| Entresto | Sacubitril/Valsartan | 69 | 23 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 68 | 17 |
| Levetiracetam | Levetiracetam | 68 | 17 |
| Celecoxib | Celecoxib | 66 | 15 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 66 | 15 |
| Fluconazole | Fluconazole | 65 | 24 |
| Spironolactone | Spironolactone | 63 | 20 |
| Tresiba Flextouch U-200 | Insulin Degludec | 63 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 63 | 19 |
| Belsomra | Suvorexant | 61 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 60 | 19 |
| Ondansetron Hcl | Ondansetron Hcl | 60 | 20 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 59 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 59 | 20 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 59 | 15 |
| Clonidine Hcl | Clonidine Hcl | 58 | 16 |
| Kerendia | Finerenone | 58 | 12 |
| Metformin Hcl Er | Metformin Hcl | 58 | 25 |
| Amitriptyline Hcl | Amitriptyline Hcl | 57 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 57 | 16 |
| Sumatriptan Succinate | Sumatriptan Succinate | 57 | 11 |
| Ezetimibe | Ezetimibe | 55 | 17 |
| Meloxicam | Meloxicam | 53 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 52 | 15 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 50 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 49 | 13 |
| Naproxen | Naproxen | 49 | 11 |
| Glipizide Er | Glipizide | 47 | 12 |
| Tresiba Flextouch U-100 | Insulin Degludec | 47 | suppressed |
| Irbesartan | Irbesartan | 46 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 45 | 15 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 44 | suppressed |
| Methocarbamol | Methocarbamol | 44 | suppressed |
| Nifedipine Er | Nifedipine | 44 | 12 |
| Trulicity | Dulaglutide | 44 | 16 |
| Sildenafil Citrate | Sildenafil Citrate | 43 | 12 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 43 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 42 | 18 |
| Levofloxacin | Levofloxacin | 42 | 30 |
| Paroxetine Hcl | Paroxetine Hcl | 42 | 13 |
| Clonazepam | Clonazepam | 41 | suppressed |
| Leucovorin Calcium | Leucovorin Calcium | 41 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 40 | suppressed |
| Dutasteride | Dutasteride | 40 | 12 |
| Ibandronate Sodium | Ibandronate Sodium | 40 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 40 | 34 |
| Novolog Flexpen | Insulin Aspart | 39 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 39 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 39 | 14 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 38 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 38 | 13 |
| Desloratadine | Desloratadine | 38 | 18 |
| Myrbetriq | Mirabegron | 38 | 12 |
| Tradjenta | Linagliptin | 38 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 37 | suppressed |
| Hydrocortisone | Hydrocortisone | 37 | 16 |
| Januvia | Sitagliptin Phosphate | 37 | 17 |
| Ketoconazole | Ketoconazole | 37 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 37 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 36 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 36 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 36 | 13 |
| Repatha Sureclick | Evolocumab | 36 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 36 | 30 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 35 | 14 |
| Nitroglycerin | Nitroglycerin | 35 | 20 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 34 | 31 |
| Latanoprost | Latanoprost | 34 | 12 |
| Valacyclovir | Valacyclovir Hcl | 33 | 20 |
| Folic Acid | Folic Acid | 32 | 11 |
| Methotrexate | Methotrexate Sodium | 32 | 11 |
| Brilinta | Ticagrelor | 31 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 31 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 31 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 31 | suppressed |
| Ondansetron Odt | Ondansetron | 31 | 13 |
| Icosapent Ethyl | Icosapent Ethyl | 30 | suppressed |
| Lofena | Diclofenac Potassium | 30 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 30 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | 11 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 29 | suppressed |
| Ibu | Ibuprofen | 29 | 13 |
| Warfarin Sodium | Warfarin Sodium | 29 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 28 | 17 |
| Fenofibrate | Fenofibrate Nanocrystallized | 28 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 28 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 28 | suppressed |
| Nystatin | Nystatin | 28 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 28 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 28 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 28 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 27 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 27 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 27 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 26 | suppressed |
| Colchicine | Colchicine | 26 | suppressed |
| Fenofibrate | Fenofibrate | 26 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | suppressed |
| Mupirocin | Mupirocin | 25 | 15 |
| Sucralfate | Sucralfate | 25 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 25 | suppressed |
| Lidocaine | Lidocaine | 24 | suppressed |
| Movantik | Naloxegol Oxalate | 24 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 24 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 23 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 22 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 22 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 22 | suppressed |
| Verapamil Er | Verapamil Hcl | 22 | suppressed |
| Bupropion Xl | Bupropion Hcl | 21 | suppressed |
| Carbamazepine | Carbamazepine | 21 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 21 | suppressed |
| Estradiol | Estradiol | 21 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 21 | suppressed |
| Lansoprazole | Lansoprazole | 21 | suppressed |
| Mesalamine | Mesalamine | 21 | suppressed |
| Metronidazole | Metronidazole | 21 | 14 |
| Pen Needles | Pen Needle, Diabetic | 21 | 12 |
| Acyclovir | Acyclovir | 20 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 20 | 19 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Testosterone | Testosterone | 20 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 20 | 11 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 15 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 19 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 18 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 19 | suppressed |
| Vascepa | Icosapent Ethyl | 19 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 18 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 18 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 18 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Klor-Con 10 | Potassium Chloride | 17 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 16 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 15 | suppressed |
| Klor-Con 8 | Potassium Chloride | 15 | suppressed |
| Otezla | Apremilast | 15 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 15 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 14 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 14 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Enbrel Sureclick | Etanercept | 14 | suppressed |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Vraylar | Cariprazine Hcl | 14 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 13 | suppressed |
| Felodipine Er | Felodipine | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Methylprednisolone | Methylprednisolone | 13 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 13 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Rexulti | Brexpiprazole | 13 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 12 | suppressed |
| Dulera | Mometasone/Formoterol | 12 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 12 | suppressed |
| Leflunomide | Leflunomide | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 12 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 12 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 11 | suppressed |
| Calcitriol | Calcitriol | 11 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Dantrolene Sodium | Dantrolene Sodium | 11 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 11 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,934.69 · 80 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, CAMZYOS, CREON, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, EYLEA, EYLEA HD, FARXIGA, JARDIANCE, JOURNAVX, Kerendia, Korlym, MOUNJARO, NUCALA, OTEZLA, Ozempic, REPATHA, REXULTI, REZDIFFRA, Rybelsus, TRELEGY ELLIPTA, TZIELD, VRAYLAR, Wegovy, ZEPBOUND, t:slim X2 Insulin Pump with Control-IQ | 21 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error